Fabian Finkelmeier

TL;DR: The progressive accumulation of exhausted, unconventionally activated CD8+PD1+ T cells in NASH-affected livers provides a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.

TL;DR: An intricate crosstalk between myeloid cell-derived ROS molecules, oxidative DNA damage, and tumor necrosis factor α-mediated signaling is identified to orchestrate a tumor-promoting microenvironment causing invasive cancer.

TL;DR: It is concluded that a high sPD-L1 level is a possible prognostic indicator for a poor outcome in HCC patients and the predictive value of sPD -L1 levels for a successful anti-PD1/PD- L1 therapy should be investigated in the future.

TL;DR: Programmed cell death protein‐1‐targeted immunotherapy has shown promising results in phase II studies of hepatocellular carcinoma.

TL;DR: The concept of immunotherapy in liver cancer with focus on nivolumab is reviewed, which is a fully human immunoglobulin G4 anti-PD-1 monoclonal antibody approved for multiple advanced malignancies and is a new treatment option for patients with advanced stage disease besides sorafenib and regorafen ib in the US.